扩增的NK细胞对胃癌细胞的杀伤作用及其机制

doi:10.13481/j.1671-587x.20200317

摘要/Abstract

摘要： 目的：探讨扩增的自然杀伤（NK）细胞对胃癌细胞的杀伤作用，阐明其作用机制。方法：提取和分离15例胃癌患者外周血单个核细胞（PBMCs）。观察扩增前后NK细胞形态表现，检测扩增前后NK细胞百分比，计算扩增后NK细胞扩增倍数，检测扩增前后NK细胞对胃癌细胞的杀伤作用，流式细胞术检测NK细胞表面活化性受体NKG2D和DNAM-1以及抑制性受体KIR2DL1和KIR3DL1的表达百分比。结果：扩增前NK细胞呈圆形，细胞体积比较小，细胞呈散在分布，扩增后NK细胞体积明显增大，细胞呈不规则形态。扩增后NK细胞百分比明显高于扩增前（P<0.01），扩增后NK细胞数是扩增前的（596±152）倍。在效靶比为5∶1时，扩增后NK细胞对胃癌细胞的杀伤活性明显强于扩增前（P<0.01）。扩增后NK细胞表面活化性受体NKG2D和DNAM-1表达百分比明显高于扩增前（P<0.01）。扩增后NK细胞表面抑制性受体KIR2DL1和KIR3DL1表达百分比明显低于扩增前（P<0.05）。结论：扩增后NK细胞对胃癌细胞杀伤作用明显强于扩增前，其机制可能与扩增后NK细胞表面活化性受体表达升高和抑制性受体表达降低有关联。

关键词: 自然杀伤细胞, 胃肿瘤, 杀伤作用, 杀伤活化性受体, 杀伤抑制性受体

Abstract: Objective: To investigate the killing effect of amplified natural killer (NK) cells on the gastric cancer cells,and to elucidate its mechanism. Methods: The peripheral blood mononuclear cells (PBMCs) from 15 patients with gastric cancer were extracted and isolated. The morphology of NK cells before and after amplification was observed, the percentages of NK cells before and after amplification were detected, and the amplification time of NK cells after amplification was calculated.The killing effects of NK cells on the gastric cancer cells before and after amplification were detected. The percentages of expressions of killing activating receptors NKG2D and DNAM-1 and killing inhibitory receptors KIR2DL1 and KIR3DL1 were detected by flow cytometry. Results: Before amplification, the NK cells were round, small in size and scattered in distribution. After amplification, the NK cells were increased in size and irregular in shape. The percentage of NK cells after amplification was significantly higher than that before amplification (P<0.01), and the number of the NK cells after amplification was (596±152) times of before amplification. When the effective target ratio was 5:1, the killing activity of NK cells on the gastric cancer cells after amplification was significantly higher than that before amplification (P<0.01).After amplification, the percentages of expressions of killing activating receptors NKG2D and DNAM-1 were significantly higher than those before amplification (P<0.01).After amplification, the percentages of expressions of killing inhibitory receptors KIR2DL1 and KIR3DL1 were significantly lower than those before amplification (P<0.05). Conclusion: The killing effect of NK cells on the gastric cancer cells after amplification is stronger than before amplification. The mechanism may be related to increasing the expressions of activated receptors and decreasing the expressions of inhibitory receptors on the surface of NK cells after amplification.

Key words: natural killer cells, stomach neoplasms, killing effect, killing activating receptor, killing inhibitory receptor

中图分类号:

R730.51

石光环, 周世平, 徐东升, 王琇. 扩增的NK细胞对胃癌细胞的杀伤作用及其机制[J]. 吉林大学学报(医学版), 2020, 46(03): 530-535.

SHI Guanghuan, ZHOU Shiping, XU Dongsheng, WANG Xiu. Killing effect of amplified NK cells on gastric cancer cells and its mechanism[J]. Journal of Jilin University(Medicine Edition), 2020, 46(03): 530-535.

参考文献

[1] FANG F, XIAO WH, TIAN Z G. NK cell-based immunotherapy for cancer[J]. Semin Immunol, 2017, 31:37-54.
[2] FEHNIGER T A, COOPER M A. Harnessing NK cell memory for cancer immunotherapy[J]. Trends Immunol, 2016, 37(12):877-888.
[3] BASSANI B, BACI D, GALLAZZI M, et al. Natural killer cells as key players of tumor progression and angiogenesis:old and novel tools to divert their pro-tumor activities into potent anti-tumor effects[J]. Cancers (Basel), 2019, 11(4):E461.
[4] XIE S L, WU Z Y, NIU L Z, et al. Preparation of highly activated natural killer cells for advanced lung cancer therapy[J]. Oncol Targets Ther, 2019, 12:5077-5086.
[5] JUENGPANICH S, SHI L, IRANMANESH Y, et al. The role of natural killer cells in hepatocellular carcinoma development and treatment:A narrative review[J]. Transl Oncol, 2019, 12(8):1092-1107.
[6] 雷子颖, 王俞, 罗嘉莉, 等. 胃癌患者外周血T淋巴细胞亚群和NK细胞分析[J]. 消化肿瘤杂志(电子版), 2018, 10(4):196-199.
[7] HAN B, MAO F Y, ZHAO Y L, et al. Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer[J]. J Immunol Res, 2018, 2018:6248590.
[8] DU Y, WEI Y. Therapeutic potential of natural killer cells in gastric cancer[J]. Front Immunol, 2018, 9:3095.
[9] REZVANI K, ROUCE R, LIU E L, et al. Engineering natural killer cells for cancer immunotherapy[J]. Mol Ther, 2017, 25(8):1769-1781.
[10] MARTIN-ANTONIO B, SUNE G, PEREZ-AMILL L, et al. Natural killer cells:angels and devils for immunotherapy[J]. Int J Mol Sci, 2017, 18(9):E1868.
[11] LI X M, HE C H, LIU C Z, et al. Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21[J]. Int J Oncol, 2015, 47(1):335-342.
[12] MUNTASELL A, OCHOA M C, CORDEIRO L, et al. Targeting NK-cell checkpoints for cancer immunotherapy[J]. Curr Opin Immunol, 2017, 45:73-81.
[13] PHAN M T, LEE S H, KIM S K, et al. Expansion of NK cells using genetically engineered k562 feeder cells[J]. Methods Mol Biol, 2016, 1441:167-174.
[14] CHENG H Y, YE X, MA R Q, et al. Experiment research of natural killer cells amplification in vitro and the killing effect on ovarian cancer cells[J]. Zhonghua Fu Chan Ke Za Zhi, 2017, 52(8):545-550.
[15] LAPTEVA N, DURETT A G, SUN J L, et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications[J]. Cytotherapy, 2012, 14(9):1131-1143.
[16] LUHM J, BRAND J M, KORITKE P, et al. Large-scale generation of natural killer lymphocytes for clinical application[J]. J Hematother Stem Cell Res, 2002, 11(4):651-657.
[17] CHILDS R W, BERG M. Bringing natural killer cells to the clinic:ex vivo manipulation[J]. Hematol Am Soc Hematol Edu Program, 2013, 2013:234-246.
[18] GRANZIN M, WAGNER J, KOHL U, et al. Shaping of natural killer cell antitumor activity by ex vivo cultivation[J]. Front Immunol, 2017, 8:458.
[19] WAGNER J, PFANNENSTIEL V, WALDMANN A, et al. A two-phase expansion protocol combining interleukin (IL)-15 and IL-21 improves natural killer cell proliferation and cytotoxicity against rhabdomyosarcoma[J]. Front Immunol, 2017, 8:676.
[20] VIVIER E, TOMASELLO E, BARATIN M, et al. Functions of natural killer cells[J]. Nat Immunol, 2008, 9(5):503-510.
[21] KRASNOVA Y, PUTZ E M, SMYTH M J, et al. Bench to bedside:NK cells and control of metastasis[J]. Clin Immunol, 2017, 177:50-59.
[22] CAROTTA S. Targeting NK cells for anticancer immunotherapy:clinical and preclinical approaches[J]. Front Immunol, 2016, 7:152.
[23] OCHOA M C, MINUTE L, RODRIGUEZ I, et al. Antibody-dependent cell cytotoxicity:immunotherapy strategies enhancing effector NK cells[J]. Immunol Cell Biol, 2017, 95(4):347-355.
[24] HILTON H G, PARHAM P. Missing or altered self:human NK cell receptors that recognize HLA-C[J]. Immunogenetics, 2017, 69(8/9):567-579.
[25] TU M M, MAHMOUD A B, MAKRIGIANNIS A P. Licensed and unlicensed NK cells:differential roles in cancer and viral control[J]. Front Immunol, 2016, 7:166.
[26] 贺丽娜,胡杨志,周轩,等.沉默PROX1表达对胃癌AGS细胞增殖和侵袭能力的影响[J].郑州大学学报(医学版),2019,54(4):559-563.